What is Abiochem?
Established in 2015 and headquartered in Shanghai, China, Abiochem operates at the forefront of genetic and enzyme engineering. The company leverages cutting-edge technologies to develop novel solutions within the biotechnology sector. Its focus on high-tech applications positions it as a key player in advancing biological sciences and engineering, aiming to translate complex scientific research into practical, high-impact products and services.
How much funding has Abiochem raised?
Abiochem has raised a total of $60.9M across 2 funding rounds:
Series B
$14.9M
Series C
$46M
Series B (2019): $14.9M, investors not publicly disclosed
Series C (2021): $46M led by CMB International Capital and Temasek
Key Investors in Abiochem
CMB International Capital
CMB International Capital is a wholly-owned subsidiary of China Merchants Bank, providing comprehensive corporate finance services and acting as an integrated financial flagship platform with a strong presence in the Hong Kong capital market.
Temasek
Temasek is a global investment company headquartered in Singapore, focused on generational investment with a forward-looking approach to making a difference.
What's next for Abiochem?
The substantial enterprise-level funding and recent strategic investment indicate Abiochem is poised for significant expansion and further technological development. This capital infusion is likely to accelerate research and development initiatives, enhance production capabilities, and potentially broaden market reach. Abiochem's trajectory suggests a focus on scaling its operations and solidifying its position as a leader in the genetic and enzyme engineering landscape, with future growth expected to be driven by continued innovation and strategic partnerships.
See full Abiochem company page
